KH903 / Chengdu Kanghong Pharma - LARVOL DELTA

Efficacy and Safety of KH903 Plus FOLFIRI as a Second-Line Treatment in Unresectable Recurrent or Metastatic Colorectal Cancer: A Randomized Phase 2 Study. (PubMed, Clin Colorectal Cancer) - "KH903 in combination with FORFIRI in second-line treatment of patients with mCRC showed prolonged mPFS and mOS, comparing to the similar agents (Avastin®, ZALTRAP®, Cyramza®) and no new safety signals were observed."

Journal • Metastases • P2 data • Colorectal Cancer • Oncology • Solid Tumor